In conclusion, our current work demonstrated a selective targeting of PP2Aa-STRN3 or STRN3-MST1/2 by the FDA-approved drugs to restore and even enhance the Hippo signal, which not only directly inhibit GC growth but also sensitize GC to chemotherapy. Here, STRN3 is linked to gastric cancer.